Hospira Recalls 5% Dextrose Injection Due to Sterility Concerns
Hospira is recalling 94,440 bags of 5% Dextrose Injection due to a potential leak at the administrative port that compromises sterility.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls are assigned a score of 4 (Severe), particularly when involving significant risks such as loss of sterility in an intravenous product.
Plain-English summary
Hospira, Inc. is recalling 94,440 bags of 5% Dextrose Injection, USP, 250 mL ADD-Vantage Unit. The affected product is identified by Lot 37-042-JT with an expiration date of January 2016. The recall is being conducted because there is a potential for the solution to leak at the administrative port of the primary container.
This leak creates a lack of assurance of sterility for the intravenous solution. The product was distributed nationwide. The recall is classified as FDA Class II, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
Healthcare providers and facilities should stop using the affected lots and contact Hospira for further instructions. Consumers should not use this prescription product and should consult their healthcare provider if they have questions regarding the recall.
The recalled product
- Product
- DEXTROSE (DEXTROSE MONOHYDRATE)
- Brand
- DEXTROSE
- Manufacturer
- Hospira Inc.
- Category
- Drug — Intravenous Solution
- Affected units
- 94,440
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 37-042-JT
- Exp 1JAN2016
UPCs (1)
- 003040409710
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DEXTROSE
- SevereDextrose Injection USP recalled due to sterility assurance concerns
FDA (Drugs) · 2026-04-29
- HighFresenius Kabi 100 mL dextrose injection bags recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- HighFresenius Kabi 5% dextrose injection bags recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- HighFresenius Kabi 50 mL dextrose injection bags recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- SeverePfizer 5% Dextrose Injection Recalled for Potential Bag Leakage
FDA (Drugs) · 2021-12-08
Same manufacturer · Hospira Inc.
See all →- CriticalHospira Recalls Dextrose Injection Syringes Due to Human Hair Particulate
FDA (Drugs) · 2017-05-31
- ModerateHospira Recalls Minibore Extension Sets Due to Solvent Occlusion
FDA (Devices) · 2017-01-18
- LowHospira Recalls Lidocaine and Dextrose Injection for Stability Failures
FDA (Drugs) · 2016-12-14
- SevereHospira Recalls Fentanyl Citrate Injection Ampules Due to Broken Tips
FDA (Drugs) · 2016-11-30
- HighHospira Symbiq Infusion Pump Recall for White Screen Safety Shutdown
FDA (Devices) · 2016-11-16
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29